The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline’s Blenrep and Sanofi’s Sarclisa) have expanded the number of options available. CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and the anti-BCMA bispecific agents (Pfizer’s elranatamab and Janssen’s teclistamab) are also expected to compete fiercely, in addition to AbbVie / Roche’s Venclexta / Venclyxto. Nevertheless, immense clinical and commercial potential remains for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and by symptomatic status.
Emerging therapies: Phase III/PR: 3 drugs; coverage of select Phase I and II products.